

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

(Securities code: 4597)

March 29, 2021

To Our Shareholders:

Yoshihiro Arai,
President and Chief Executive Officer
Solasia Pharma K.K.
4F, SUMITOMO FUDOSAN SHIBA-
KOEN TOWER, 2-11-1, Shiba-koen,
Minato-ku, Tokyo

Notice of the Resolutions Adopted at the 13th Annual General Meeting of Shareholders

Solasia Pharma K.K. (the “Company”) is pleased to inform you that the matters noted below were reported and resolved at the 13th Annual General Meeting of Shareholders held on March 29, 2021.

Reported Item The Business Report, the Consolidated Financial Statements and the Non-Consolidated Financial Statements for the 12th fiscal year (from January 1, 2020 to December 31, 2020), and the results of audits of the Consolidated Financial Statements by the Independent Auditor and the Audit & Supervisory Board.

This item was reported at the meeting accordingly.

Resolved Items

Proposal No. 1: Election of Five Board Directors
This was approved and resolved as originally proposed. Five (5) directors, namely, Yoshihiro Arai, Toshio Miyashita, Stanley Lau, Norikazu Eiki, and Jiro Mizukawa were elected; and all assumed their offices.

Proposal No. 2: Partial Amendments to the Articles of Incorporation
This was approved and resolved as originally proposed.

-END-